FDA Fast Tracks LTI-03 for Idiopathic Pulmonary Fibrosis

The FDA has granted Fast Track designation to LTI-03, an inhaled peptide therapy from Rein Therapeutics (NASDAQ: RNTX), for idiopathic pulmonary fibrosis (IPF).^¹

The designation, announced August 20, 2026, follows a prior Orphan Drug designation already granted to LTI-03 for IPF.^¹ Currently approved antifibrotic therapies slow disease progression but do not halt it, leaving room for agents with reparative as well as antifibrotic mechanisms.^¹ LTI-03's Caveolin-1-derived mechanism sets it apart from existing antifibrotics by targeting alveolar epithelial repair alongside fibrotic signaling.^¹

“Receiving Fast Track designation for LTI-03 from the FDA marks a significant milestone for Rein, and underscores the urgent need for new treatment options that can not only halt disease progression, but also potentially support tissue repair and regeneration,” said Brian Windsor, President and CEO, Rein Therapeutics.^¹ The company said the designation gives it an opportunity to work closely with the FDA as enrollment in RENEW continues.^¹

What is LTI-03’s mechanism of action and the RENEW phase 2 trial design?

LTI-03 is a first-in-class, inhaled peptide therapy derived from Caveolin-1 biology.^¹ According to Rein Therapeutics, the peptide targets fibrotic signaling pathways while preserving alveolar progenitor cells needed for lung tissue repair and regeneration.^¹ The company reports early evidence suggesting LTI-03 may simultaneously slow fibrosis progression and promote lung healing, a dual mechanism distinct from currently approved antifibrotics.^¹

The RENEW Phase 2 trial is a randomized, placebo-controlled study enrolling approximately 120 patients across 5 countries: the United States, United Kingdom, Australia, Poland, and Germany.^¹ Participants are randomized to 1 of 2 LTI-03 dose levels or placebo.^¹

Primary endpoints include safety through week 24 and change in forced vital capacity (FVC) from baseline, the standard efficacy measure in IPF trials.^¹ Rein Therapeutics is actively enrolling patients and anticipates sharing interim results in the second half of 2026.^¹

What does the regulatory pathway for LTI-03 look like?

Fast Track is a regulatory pathway for drugs treating serious conditions and filling an unmet medical need, allowing more frequent interactions with the FDA during development and potential eligibility for rolling review of a future marketing application.^² Sponsors granted Fast Track designation also receive more frequent meetings with the FDA on the drug's development plan and additional written guidance on trial design, according to the agency.^² For Rein Therapeutics, the designation adds to the Orphan Drug designation previously granted to LTI-03 for IPF.^¹

No safety or efficacy data from the RENEW trial have been reported publicly, since the study remains in active enrollment.^¹ Rein Therapeutics has not disclosed adverse events of special interest or discontinuation rates at this stage.^¹ Comparative safety and secondary endpoint data are not yet available, and clinicians should await interim results expected later in 2026 before drawing conclusions about the tolerability profile of LTI-03.^¹

Rein Therapeutics describes itself as a clinical-stage biopharmaceutical company focused on first-in-class therapies for orphan pulmonary and fibrotic indications.^¹ Interim data from the RENEW trial, expected in the second half of 2026, will inform continued development of LTI-03 and ongoing engagement with the FDA under Fast Track designation.^¹

The designation comes as other antifibrotic candidates continue to advance in IPF.^³ A recent pooled analysis of nerandomilast reported a reduction in mortality risk, reflecting persistent interest in agents beyond the 2 currently approved antifibrotics.^³

References

1. Rein Therapeutics. Rein Therapeutics receives U.S. FDA Fast Track designation for LTI-03 in idiopathic pulmonary fibrosis. Published August 20, 2026. Accessed August 20, 2026. https://www.globenewswire.com/news-release/2026/08/20/3348293/28652/en/rein-therapeutics-receives-u-s-fda-fast-track-designation-for-lti-03-in-idiopathic-pulmonary-fibrosis.html

2. US Food and Drug Administration. Fast Track. Accessed August 20, 2026. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

3. HCPLive. Nerandomilast reduces mortality risk in pulmonary fibrosis analysis. https://www.hcplive.com/view/nerandomilast-reduces-mortality-risk-pulmonary-fibrosis-analysis. Published July 31, 2026. Accessed August 20, 2026.